MTOR and lymphoma: In our opinion, future research on the use of mTOR inhibitors in lymphoid malignancies should aim in three basic fields: (a) identification of the whole spectrum of molecular alterations that are related to mTOR signaling dysregulation in each lymphoma subtype, (b) definition of the subset of patients who are likely to respond best to anti-mTOR treatment, and (c) design of new clinical trials aiming to determine the effectiveness of mTOR-inhibitors in the context of established or other; targeted or nontargeted; treatment.